Rapport Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
RAPP$26.07+6.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share data)
| December 31,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $52,645 | $56,805 |
| Short-term investments | 437,894 | 248,475 |
| Restricted cash | 105 | 105 |
| Prepaid expenses and other current assets | 7,917 | 4,417 |
| Total current assets | 498,561 | 309,802 |
| Property and equipment, net | 2,976 | 3,529 |
| Operating lease right of use asset, net | 9,909 | 1,442 |
| Other assets | 985 | 160 |
| Total assets | $512,431 | $314,933 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $4,190 | $1,954 |
| Accrued expenses and other current liabilities | 12,104 | 6,076 |
| Operating lease liability | 2,755 | 737 |
| Total current liabilities | 19,049 | 8,767 |
| Operating lease liability, net of current portion | 8,729 | 739 |
| Total liabilities | 27,778 | 9,506 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity | ||
| Undesignated preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; zero shares issued and outstanding at December 31, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024; 47,772,567 shares and 36,580,202 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 48 | 37 |
| Additional paid-in capital | 719,287 | 429,657 |
| Accumulated other comprehensive income (loss) | 546 | (522) |
| Accumulated deficit | (235,228) | (123,745) |
| Total stockholders’ equity | 484,653 | 305,427 |
| Total liabilities and stockholders’ equity | $512,431 | $314,933 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.